United States-based Mylan has acquired an exclusive license to commercialise a biosimilar to Humira (adalimumab), developed by Fujifilm Kyowa Kirin Biologics, in Europe, it was reported yesterday.
The collaboration allows Mylan to leverage its regulatory platform to seek approval and commercialise the product in Europe. According to the terms of the contract between both firms, Fujifilm Kyowa Kirin Biologics grants Mylan an exclusive license to commercialise the adalimumab biosimilar in Europe and will receive an up-front fee. In addition, Fujifilm Kyowa Kirin Biologics is eligible to receive a subsequent commercialisation milestone payment and sales royalties. Mylan will be responsible for the sales activity of the product in European countries.
The product is a TNF-inhibitor intended for treating multiple chronic inflammatory conditions. It is indicated in Europe for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa and uveitis.
According to IQVIA, Humira is the world's best-selling biologic medication with brand sales of approximately USD4.1 billion in Europe for the 12 months ending Dec. 31, 2017.
Chemomab secures new patents for CM-101 monoclonal antibody
argenx receives FDA priority review for VYVGART Hytrulo in CIDP
Diamyd Medical granted US FDA Fast Track designation for Diamyd diabetes treatment
Ono partners with Shattuck Labs for bifunctional fusion proteins
Artax Biopharma doses first subject in AX-158 Phase 2a psoriasis trial
Innovent Biologics announces CFO transition
Bio-Thera Solutions commences dosing in BAT6026 Phase IA/IIB clinical trial
BioSenic expands patent coverage for ATO therapeutic platform
Celltrion USA submits CT-P47 Biologics License Application to FDA
NS Pharma's NS-229 receives European Commission orphan drug designation
Kyverna Therapeutics' KYV-101 granted US FDA fast track designation
InnoCare Pharma receives U.S. FDA clearance for ICP-248 clinical trial